Dear All, Novel antibacterial agents, vaccines, and diagnostics will do little if they are not widely available and used responsibly. CDDEP’s recent report entitled “The
Dear All: Two new events on the near-term horizon. First, FDA has announced an Antimicrobial Drugs Advisory Committee for 11 Jan 2018 (and materials from the meeting
Dear All, Happy New Year! As a great start for January, Team CARB-X have announced (i) that they will have two funding calls during 2026 (April
Dear All (and with thanks to Kevin Outterson for being lead author on this newsletter), (wonkish alert on this one … refresh your coffee and
Dear All (addendum: see also the 22 Dec 2025 follow-up newsletter), I wrote in a 12 Dec 2024 newsletter (“Mirror Bacteria: An AMR threat of unprecedented
Dear All (and with thanks to Patricia Bradford for co-authoring this newsletter), When you are seeking novelty, antibacterial discovery is hard … really, really, REALLY
Note: As always, please use the copy of the newsletter posted at https://amr.solutions/ if you have trouble with links in this newsletter. Dear All, As I
Dear All, The 8 Dec 2025 newsletter entitled “Phage therapy: Regulatory perspectives from TATFAR” generated a fair bit of commentary! I’ve now added several post-newsletter
Dear All, Integrating perspectives from EC HERA, EMA, Health Canada, Norway, UK MHRA, US FDA, and US NIH, the Transatlantic Task Force on AMR (TATFAR)’s
See also This related newsletter: 14 Jul 2022, entitled “WHO Vaccine Pipeline Review; CDC On Impact Of COVID On AMR.” This 20 Oct 2024 report